Cardiovascular toxicity often hinders success – are companies picking the wrong compounds?
Prolific novelist and academic CS Lewis once said, “Failures are finger posts on the road to achievement.” (Given pharma’s drug failure rate, the road ahead must truly be paved in gold.)
When it comes to drug safety failure, toxicity – especially to the cardiovascular system – is a major stumbling block. In an effort to learn from past failures and help improve success rates, ApconiX and PhysioStim have teamed up to create a European Center of Excellence for Preclinical Cardiovascular Safety Evaluation. The companies hope to provide high-throughput screening to help pharma companies decide whether their compound is on the right track to pass safety tests. Here, we speak with a spokesperson from ApconiX to learn more.
Read more here: Learning from Failure